← All trials
NCT00486044
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2005
- Primary completion
- Jun 1, 2009
- Completion date
- Jun 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 103
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of WisconsinLead sponsor
- National Institute on Aging (NIA)Collaborator
- MerckCollaborator
- University of WisconsinOverall official - principal investigator
- Paul Beeson Faculty Scholars ProgramCollaborator
- The John A. Hartford FoundationCollaborator
- The Atlantic PhilanthropiesCollaborator
- Starr FoundationCollaborator
- American Federation for Aging ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.